Table 2 Baseline characteristics of the participants
Serial number | Age | Gender | BMI | Allergy history | Smoking history | Disease duration | Comorbidities | Diagnosis |
|---|---|---|---|---|---|---|---|---|
001 | 66 | Male | 26.675 | None | 1000 | 5 y + | None | COPD (Chronic Obstructive Pulmonary Disease.) with pulmonary fibrosis |
002 | 65 | Male | 21.231 | None | none | 1 y + | Hyperlipidemia | Post-inflammatory pulmonary fibrosis |
003 | 65 | Female | 27.055 | None | none | 10 y + | Bronchiectasis, hyperlipidemia | Emphysema with pulmonary fibrosis |
004 | 69 | Male | 23.588 | None | 1040 | 9 m + | Rheumatic heart disease, post-mitral valve replacement, cerebral infarction, chronic gastritis | Emphysema with pulmonary fibrosis |
005 | 71 | Male | 19.047 | None | 80 | 5 y + | None | COPD with pulmonary fibrosis |
006 | 65 | Male | 24.655 | None | 300 | 1 y + | Inactive pulmonary tuberculosis | Idiopathic Pulmonary Fibrosis (IPF) |
007 | 55 | Male | 21.755 | None | none | 5 y | Splenectomy | Interstitial lung disease (ILD) |
008 | 60 | Female | 20.202 | None | none | 3 y | Bronchiectasis, type 2 diabetes, hyperlipidemia, hypertension, gallstones | COPD with pulmonary fibrosis |
009 | 69 | Male | 20.703 | None | none | 9 m + | Bronchiectasis, non-tuberculous mycobacterial lung disease, COVID-19 | Post-inflammatory pulmonary fibrosis |
010 | 63 | Male | 24.167 | None | 600 | 2 y + | Bronchiectasis, hypertension, hyperlipidemia | COPD with pulmonary fibrosis |
011 | 58 | Female | 29.997 | None | none | 3 y + | Type 2 diabetes, hypertension, hyperlipidemia, hyperuricemia, arteriosclerosis, fatty liver, thyroid nodules | Interstitial lung disease (ILD) |
012 | 76 | Male | 27.513 | None | 600 + | 6 y + | Hyperlipidemia, fatty liver, pulmonary nodules | COPD with pulmonary fibrosis |
013 | 58 | Female | 21.228 | None | none | 1 y + | Anti-synthetase syndrome | Interstitial lung disease (ILD) |
014 | 53 | Female | 24.524 | None | none | 2 y + | Anti-synthetase syndrome | Interstitial lung disease (ILD) |
015 | 79 | Male | 24.741 | None | 800 | 1 y + | COPD | Post-inflammatory pulmonary fibrosis |
016 | 69 | Female | 20.408 | None | none | 8 y | Scleroderma | ILD |
017 | 65 | Male | 21.231 | None | 400 + | 1 y + | None | COPD with pulmonary fibrosis |
018 | 64 | Male | 23.384 | None | 600 + | 1 y + | COPD | Post-inflammatory pulmonary fibrosis |
019 | 69 | Male | 18.508 | None | 1000 | 1 y + | None | COPD with pulmonary fibrosis |
020 | 65 | Female | 22.959 | None | none | 3 y + | ANCA-associated vasculitis | ILD |
021 | 68 | Female | 23.873 | None | none | 5 y + | Polymyositis | ILD |
022 | 56 | Male | 22.833 | None | 800 | 1 y | Hypertension | COPD with pulmonary fibrosis |
023 | 49 | Male | 18.218 | None | 800 | 1 y + | Arrhythmia, coronary artery sclerosis, alcoholic liver disease, cholestasis, chronic gastritis, duodenal bulb inflammation | COPD with pulmonary fibrosis |
024 | 57 | Male | 15.822 | None | 1000 | 2 y + | History of left upper lobe pulmonary bullae surgery | COPD with pulmonary fibrosis |
